ArticleFrontiers in veterinary science2026
Discovery of novel biomarkers associated with myocardial fibrosis in chimpanzees (
Article in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic myocardial fibrosis (IMF) is a prevalent and life-threatening condition in captive chimpanzees ( Methods: Serum samples collected from zoo-housed chimpanzees with post-mortem confirmed cardiac phenotypes were utilized. An initial discovery phase using a Proximity Extension Assay (PEA) screened 92 cardiovascular proteins in a subset of 10 chimpanzees. Three candidate biomarkers (ICAM-2, AXL, and PECAM-1) were subsequently selected for Enzyme-Linked Immunosorbent Assay (ELISA) validation in a broader cohort ( Results: In the discovery phase, ICAM-2, AXL, and PECAM-1 were significantly elevated in IMF-affected animals. During ELISA validation, circulating ICAM-2 remained significantly elevated in the IMF cohort ( Conclusion: ICAM-2 is a highly specific, putative "rule-in" biomarker for moderate-to-severe IMF in chimpanzees. Implementing this biomarker into routine health assessments could enhance the early, non-invasive detection and clinical management of cardiovascular disease in this endangered species, though further validation is required before wider clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.